Earlier MI Diagnosis with Sensitive Cardiac Troponin

Author: Katherine Soreng, PhD, Director, Clinical and Scientific Liaisons, Siemens Healthcare Diagnostics

The World Health Organization reports that cardiovascular disease is the number one cause of death in the industrialized world. Of the deaths attributed to CVD, an estimated 7.3 million were due to coronary heart disease, with another 6.2 million deaths caused by stroke. In an emergency situation, cardiologists and urgent care physicians face the same challenge in triaging patients who present with chest pain: (1) is this patient experiencing a cardiac event? (2) if not, how soon can I confidently rule him/her out? and (3) if so, how soon can I get him/her the care he/she needs?

Cardiac troponin, the preferred biomarker in myocardial infarction (MI) testing due to its specificity of myocardial damage (elevated in all AMIs), is one of the tools clinicians have at their disposal to aid in the earlier diagnosis of MI

Learning objectives:

  • Review the current troponin testing guidelines
  • Learn about the comparability of guideline approved sensitive and high sensitive assays in the earlier diagnosis of MI
  • Understand how to use serial measurements, especially patients with non-ST-elevation acute myocardial infarction


Webinars are complimentary and remain available online for 12 months after the live webinar date. Log on and learn!

For additional information on troponin, visit

Date: 2015-04-22

Did this information help you?
Thank you for your response
We detected numbers and/or an '@' symbol in your comment. Are you trying to enter a phone number or email address so that we may contact you, please contact us via our email form instead.

Note: to get a direct personal response, please contact us via our email form.

Thank you